PF-06882961 是一种 GLP-1R 激动剂。在 II 期研究中，它作为 2 型糖尿病治疗的候选药物。

Liraglutide是一种胰高血糖素样肽-1（GLP-1）受体激动剂，常用于2型糖尿病的临床治疗。

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).

GRA Ex-25 is an inhibitor of glucagon receptor, with IC50 of 56 and 55 nM for rat and human glucagon receptors, respectively.

Teduglutide , an analog of glucagon-like peptide 2, improves intestinal rehabilitation by promoting mucosal growth and possibly by inhibiting gastric emptying and secretion, which in turn reduces intestinal losses and promotes intestinal absorption.

GLP-1(7-37) is an insulinotropic peptide generated from the precursor peptide GLP-1(1-37).

Glucagon is a peptide hormone, exhibits therapeutic potential for metabolic disease.

Semaglutide is an analog of human GLP-1 with long-acting effect over the other GLP-1Ras.

BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC50s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively.

Glucagon receptor antagonists-4 is an selective antagonist of glucagon receptor.

Exendin Fragment 9-39 is an antagonist of glucagon-like peptide-1 (GLP-1) receptor, and also acts as an inhibitor of glucosedependent insulinotropic polypeptide (GIP)-receptor binding.

Exendin-4 is a high affinity glucagon-like peptide 1 (GLP-1) receptor agonist (Kd = 136 pM) and originally isolated from Heloderma suspectum venom.

Ubiquitin Isopeptidase Inhibitor I, G5 is an apoptosome-independent caspase and apoptosis activator.